Multiple Myeloma, Multiple Sclerosis, Breast Cancer Drugs Are Among Those Going Off Patent in 2020

AIS Health asked various industry experts about what specialty drugs are expected to see patent expiration — and potentially generic or biosimilar competition — in 2020. Here’s what Martin Burruano, R.Ph., vice president, pharmacy services at Independent Health; April M. Kunze, Pharm.D., senior director, clinical formulary development and trend management strategy at Prime Therapeutics LLC; and Mesfin Tegenu, R.Ph., president of PerformRx, LLC, told us:

✦ Eligard (leuprolide acetate): prostate cancer,

✦ Forteo (teriparatide): osteoporosis,

✦ Juxtapid (lomitapide): familial hypercholesterolemia,

✦ Korlym (mifepristone): endocrine gland diseases,

✦ Lucentis (ranibizumab): macular degeneration,

✦ Pomalyst (pomalidomide): multiple myeloma,

✦ Sprycel (dasatinib): acute lymphoblastic leukemia and chronic myeloid leukemia,

✦ Tecfidera (dimethyl fumarate): multiple sclerosis (MS),

✦ Thalomid (thalidomide): multiple myeloma and leprosy,

✦ Truvada (emtricitabine/tenofovir disoproxil fumarate): HIV-1 infection and HIV pre-exposure prophylaxis (PrEP),

✦ Tykerb (lapatinib): breast cancer, and

Tysabri (natalizumab): MS.

0

0

0 Comments

0

0

• Radar on Specialty Pharmacy